Announced details
Pediatric liver tumors, hepatoblastoma, pediatric solid tumors
The Company is conducting joint research with the institution as a research partner.
A public research institution in Barcelona. It conducts cutting-edge translational research and innovation, partners with leading university hospitals in Barcelona, and conducts research in 9 areas, including cancer. Location: Barcelona.
The Company states that it will pursue efforts to out-license the technology to pharmaceutical companies, but no specific impact on financial results from this matter is stated.
The company does not address Contract Value / Offering price.
SIOPEL 2026 Spring Meeting and the conference website (https://biomedia.net/15848/)
| Item | Details |
|---|---|
| Names of Products / Services Covered | CBA-1205 |
| Counterparty | Germans Trias i Pujol Research Institute（IGTP） |
| Counterparty overview | A public research institution in Barcelona. It conducts cutting-edge translational research and innovation, partners with leading university hospitals in Barcelona, and conducts research in 9 areas, including cancer. Location: Barcelona. |
| Relationship with the Company | The Company is conducting joint research with the institution as a research partner. |
| Applicable area | Pediatric liver tumors, hepatoblastoma, pediatric solid tumors |
| Impact on Business Performance | The Company states that it will pursue efforts to out-license the technology to pharmaceutical companies, but no specific impact on financial results from this matter is stated. |
| Source | SIOPEL 2026 Spring Meeting and the conference website (https://biomedia.net/15848/) |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To announce the results of joint research with the Germans Trias i Pujol Research Institute (IGTP).